GRANDPHARMA: MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 30 APRIL 2024
May 3 17:28
GRANDPHARMA: Notice of availability to Registered Shareholders and Reply Form
Apr 26 22:33
GRANDPHARMA: Notice of availability to Non-registered Shareholders and Reply Form
Apr 26 22:32
GRANDPHARMA: ESG Report 2023
Apr 26 22:32
GRANDPHARMA: Proxy form for the annual general meeting to be held on Tuesday, 4 June 2024 or any adjournment thereof
Apr 26 22:31
GRANDPHARMA: Notice of Annual General Meeting
Apr 26 22:31
GRANDPHARMA: (1) GENERAL MANDATE TO REPURCHASE SHARES AND ISSUE NEW SHARES; (2) RE-ELECTION OF RETIRING DIRECTORS AND CONTINUOUS APPOINTMENT OF INDEPENDENT NON-EXECUTIVE DIRECTOR SERVING MORE THAN NINE YEARS; AND (3) NOTICE OF ANNUAL GENERAL MEETING
Apr 26 22:30
GRANDPHARMA: Annual Report 2023
Apr 26 22:30
GRANDPHARMA: MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 31 MARCH 2024
Apr 3 19:42
GRANDPHARMA: VOLUNTARY ANNOUNCEMENT: THE GROUP INTRODUCES A GLOBAL INNOVATIVE PRODUCT FOR THE TREATMENT OF DEMODEX BLEPHARITIS AND MEIBOMIAN GLAND DISEASE WITH DEMODEX MITES
Mar 27 17:20
GRANDPHARMA: Final dividend for the year ended 31 December 2023
Mar 27 17:19
GRANDPHARMA: Final dividend for the year ended 31 December 2023
Mar 26 18:03
GRANDPHARMA: THE GLOBAL INNOVATIVE RDC DRUG OF THE GROUP ITM-11 IS APPROVED TO CONDUCT PHASE III CLINICAL STUDY IN CHINA
Mar 24 18:13
GRANDPHARMA: Final dividend for the year ended 31 December 2023
Mar 21 19:45
GRANDPHARMA: Clarification Announcement in relation to Closure of Register of Members
Mar 21 19:44
GRANDPHARMA: Final dividend for the year ended 31 December 2023
Mar 20 06:02
GRANDPHARMA: ANNOUNCEMENT OF ANNUAL RESULTS FOR THE YEAR ENDED 31 DECEMBER 2023
Mar 20 06:01
GRANDPHARMA: DATE OF BOARD MEETING
Mar 7 17:40
GRANDPHARMA: VOLUNTARY ANNOUNCEMENT: THE GROUPS GLOBAL INNOVATIVE OPHTHALMIC DRUG GPN00884 WAS APPROVED TO CONDUCT PHASE I CLINICAL STUDY IN CHINA
Mar 7 17:36
GRANDPHARMA: VOLUNTARY ANNOUNCEMENT: THE NDA OF A GLOBAL INNOVATIVE HORMONE NANOSUSPENSION EYE DROPS WAS APPROVED BY THE FDA
Mar 7 17:33
No Data
No Data